Bibliography
Ceryl Lynn Besch
1. Jacobson MA, Besch CL, Child C et al. Community programs for clinical research on AIDS: description of a randomized prospective study of clindamycin versus pyrimethamine for prevention of Toxoplasma gondii infection. Eur J Clin Microbiol Infect Dis 1991;10:195-198.
2. Jacobson MA, Besch CL, Child C, et al. Toxicity of clindamycin as prophylaxis for AIDS associated toxoplasmic encephalitis. Lancet 1992;339:333-334.
3. Jacobson MA, Besch Cl, Child c, et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced HIV disease. J Infect Dis 1994;169:384-394.
4. Besch CL. Compliance in clinical trials. AIDS 1995;9:1-10.
5. Morse EV, Besch Cl, Simon PM. Issues of recruitment, retention and compliance in community based clinical trials with traditionally under served populations. Applied Nursing Res 1995:8:8-14.
6. Webster CT, Gordin FM, Matts JP, Korvick JA, Miller C, Muth K, Brown LS, Besch Cl, et al. Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection. Am J Res Crit Care med 1995:151:805-808.
7. Gordin FM, Neslon ET, Matts JP, Cohn DL, Ernst J, Benator D, Besch Cl, et al. The impact of human immunodeficiency virus on drug-resistant tuberculosis. Am J Resp Crit Care med 1995;154:1478-1483.
8. Schuman P, Capps L, Peng G, Vazquez J, El-Sadr W, Goldman AI, Alston B, Besch CL, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: a randomized, double-blind, placebo-controlled trial. Ann Int Med 1996;126:689-696.
9. Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John S, Klein M, Vaughn A, Besch CL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. N Engl J Med 1997;337:315-320.
10.
MacArthur, R. D., L. Chen, et al. (2001). "The rationale
and design of the CPCRA (Terry Beirn Community Programs for Clinical Research
on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies)
trial." Control Clin Trials 22(2):
176-90.
11. Martin JE, Besch CL; U.S. Public Health Service; Infectious Diseases Society of America. Prophylaxis against opportunistic infections in persons infected with human immunodeficiency virus. Am J Med Sci. 2004 Jul;328(1):64-9.
12.
Clark RA, Wilcox R, Besch CL. The antiretroviral-experienced
patient.
13.
Am J Med Sci. 2004 Jul;328(1):10-6.
14.
Besch CL.Antiretroviral therapy in drug-naive patients
infected with human immunodeficiency virus. Am J Med Sci. 2004 Jul;328(1):3-9.
15.
O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns
and correlates of discontinuation of the initial HAART regimen in an urban
outpatient cohort. J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):407-14.
16.
Farley TA, Cohen DA, Wu SY, Besch CL.The value of
screening for sexually transmitted diseases in an HIV clinic. J Acquir Immune
Defic Syndr. 2003 Aug 15;33(5):642-8.
Abstracts
1. Besch CL, Morse EV, Simon PM, et al. Determinants of levels of compliance in patients enrolled in a PCP prophylaxis protocol. X International Conference on AIDS, Yokohama, 1994.
2. Gibert C, Launer C, Bartsch G, Muurahainen D, Abrams D, Besch Cl, Wheeler D and the Terry Beirn Community Programs for Clinical research on AIDS. Body weight and per cent change as a predictor of mortality in HIV, poster 156, 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.
3. Wheeler, D, Launer C, Bartsch G, Muurahainen D, Besch Cl, Seranis D, Gibert C and the Terry Beirn Community Programs for Clinical Research on AIDS, poster 157, 35th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1995.
4. Simon PM, Morse EV, Besch CL. Barriers to compliance among women co-enrolled in a PCP Prophylaxis and compliance protocol. poster, HIV IN Women Conference, Washington, D.C., 1995.
5. Besch CL, Morse EV, Simon PM, Hodges J, Franchino B for the Terry Beirn Community Programs for Clinical Research on AIDS. Preliminary results of a compliance study within the CPCRA 007 combination nucleoside study. Poster, 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C., 1996.